The transgenic mouse model for reversible activation of physiological levels of p53 will be used to investigate the contribution of the loss of the p53 pathway to brain tumor formation and growth with the long-term goal of evaluating the therapeutic potential of this tumor suppressor for glioma treatment.
The specific aims are 1) to determine whether re-activation of p53 can prevent, retard or reverse carcinogen-induced brain tumors in mice and to elucidate which attribute of p53 function affects gliomagenesis; 2) to define molecular lesions required for gliomagenesis and investigate the role of p53 in modulating glioma invasion; 3) to engineer conditional transgenic mice models for oncogene-induced glioma formation and to determine the role of p53 in this process. The consequences of p53 re-activation in the brain tumors that developed without active p53 will be monitored by MRI. CGH analysis will be employed to detect genomic alterations required for glioma occurrence. The microdissection of brain tissue and subsequent microarray analysis will reveal the spectrum of p53 response in vivo during the various stages of glioma formation. Overall, the proposed research will significantly contribute to the understanding of gliomagenesis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F09 (20))
Program Officer
Lohrey, Nancy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Brindle, Nicola R; Joyce, Johanna A; Rostker, Fanya et al. (2015) Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer. PLoS One 10:e0120348
Shchors, Ksenya; Persson, Anders I; Rostker, Fanya et al. (2013) Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A 110:E1480-9
Shchors, K; Nozawa, H; Xu, J et al. (2013) Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. Oncogene 32:502-13
Soucek, Laura; Lawlor, Elizabeth R; Soto, Darya et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211-8
Shchors, Ksenya; Evan, Gerard (2007) Tumor angiogenesis: cause or consequence of cancer? Cancer Res 67:7059-61
Shchors, Ksenya; Shchors, Elena; Rostker, Fanya et al. (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 20:2527-38
Finch, Andrew; Prescott, Julia; Shchors, Ksenya et al. (2006) Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell 10:113-20